

FORM 7

MONTHLY PROGRESS REPORT

For January 2018

Name of Listed Issuer: **Liberty Health Sciences Inc. (formerly, SecureCom Mobile Inc.)** (the "Issuer" or "Company").

Trading Symbol: **LHS**

Number of Outstanding Listed Securities: **284,543,026 common shares**

Date: **February 7, 2018**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company had an active month of January with a number of initiatives on different fronts.

On January 4th, the company announced the proposed acquisition of a 387 acre parcel of land in Gainesville, Florida, that includes 200,000 square feet of greenhouses and processing space ("Alico"). Since that time, the Company has completed due diligence and on January 31st, announced that the entering into of a definitive agreement for the purchase, which expected to close February 9, 2018. The Company plans to retrofit the facility over the coming months and in the meantime, will continue to cultivate and process out of the existing Chestnut Hill facility. The Phase 2 greenhouse build-out at Chestnut Hill is now completed and the Company expects to commence cultivation in the new space in early February.

On January 16th, the Company announced the opening of the first dispensary in the Villages area in central Florida. In addition, several new locations are planned over the coming months.

On January 17th, the Company announced an exclusive licensing agreement with MC Brands (incredibles), a leading producer of cannabis edibles, wellness products and extracts, to provide a complementary suite of medical cannabis products to patients in Florida.

On January 31st, the Company announced the previously announced bought deal equity financing of units of the Company was mutually terminated by the Company and the underwriters, Clarus Securities Inc. and AltaCorp. Capital Inc., in accordance with the terms of the Underwriting Agreement dated January 10, 2018.

On February 2nd, the Company announced the acquisition of Aphria Inc.'s minority membership interests in Copperstate Farms, LLC and Copperstate Farms Investors, LLC (collectively "Copperstate") for a purchase price of \$20 million. The transaction is subject to customary conditions of closing, including the satisfaction or waiver of a right of first offer in favour of existing Copperstate investors. The transaction is expected to close in the second quarter.

On February 5th, the Company announced that a group of buyers led by members of the Serruya family has entered into a purchase and sale agreement with Aphria Inc. ("Aphria") to purchase all of Aphria's shares in the Company that are not subject to Canadian Securities Exchange ("CSE") escrow requirements over the course of the next two and a half years. The Transaction strengthens Liberty's aggressive growth plans in the U.S. cannabis market by welcoming the Serruya family as new strategic partners with significant U.S. retail and cannabis industry experience. The Company will benefit from the Serruya family's interest in the Company and the long-term strategic partnership with Aphria, while at the same time enabling Aphria to satisfy the opinions of the Toronto Stock Exchange regarding its investments in the U.S. The Company will retain full access to Aphria's Intellectual Property, Know-How, Branding and key management personnel.

The Company intends to continue to look at strategic avenues for growth including, but not limited to, evaluating targets for expansion in key U.S. states that have approved medical use of marijuana and meet its stringent investment criteria.

2. Provide a general overview and discussion of the activities of management.

In addition to overseeing the construction of Phase 2 expansion at Chestnut Hill in Florida, the acquisition of the Alico facility and planning for the retrofit activities has been a focus in the last month.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

As mentioned above, the Company entered into a licensing agreement with MC Brands to produce and sell their incredible brand of edibles and wellness products. Under the terms of the agreement, Liberty will be the exclusive producer and provider of incredible cannabis products in Florida, subject to receipt of all required approvals from the Florida Department of Health, Office of Medical Marijuana Use.

No other changes to report in the month of January.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report in the month of January.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report in the month of January.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report in the month of January.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report in the month of January.

8. Describe the acquisition of new customers or loss of customers.

The Company continues to grow its number of patients as the overall Florida market increases in terms of registered patients.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None to report in the month of January.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Company continues to add personnel in the areas of patient care and product deliveries in the Florida operations as well as dispensaries with the opening of the Villages store.

There were no significant terminations or lay-offs in the month of January.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report in the month of January.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report in the month of January.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

No new debt to report for the month of January.

14. Provide details of any securities issued and options or warrants granted.

None to report in the month of January.

15. Provide details of any loans to or by Related Persons.

None to report in the month of January.

16. Provide details of any changes in directors, officers or committee members.

None to report in the month of January.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

There were no significant change in trends and risks in the month of January which are likely to impact the Company during the period.

On January 4, 2018, the US Attorney General, Jeff Sessions, issued a memo concerning the enforcement of the US Federal laws regarding the use of marijuana, which is a federally banned substance. It is unclear what impact, if any, this will have on companies such as Liberty who operate within a legal state framework in the US.

On the same day, the Company responded reiterating that "Liberty is a licensed medical cannabis company that strictly adheres to the laws in the U.S. states in which we operate. As a medical cannabis company, we are protected against enforcement by enacted legislation from U.S. Congress in the form of the Rohrabacher-Blumenauer amendment."

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. To the best of the undersigned's knowledge and belief, as of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that, to the best of the undersigned's knowledge and belief, the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. To the best of the undersigned's knowledge and belief, all of the information in this Form 7 Monthly Progress Report is true.

Dated February 7, 2018.

Rene Gulliver
Name of Director or Senior Officer

"Rene Gulliver"
Signature

CFO
Official Capacity

Issuer Details Name of Issuer Liberty Health Sciences Inc. (formerly, SecureCom Mobile Inc.)	For Month End January 31, 2018	Date of Report YY/MM/DD 18/02/07
Issuer Address 35 McCaul Street, 2nd Floor		
City/Province/Postal Code Toronto, ON M5T 1V7	Issuer Fax No.	Issuer Telephone No.
Contact Name Rene Gulliver	Contact Position CFO	Contact Telephone 416-884-0791
Contact Email Address rgulliver@libertyhealthsciences.com	Web Site Address https://libertyhealthsciences.com/	